PE61899A1 - Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico - Google Patents

Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Info

Publication number
PE61899A1
PE61899A1 PE1998000177A PE00017798A PE61899A1 PE 61899 A1 PE61899 A1 PE 61899A1 PE 1998000177 A PE1998000177 A PE 1998000177A PE 00017798 A PE00017798 A PE 00017798A PE 61899 A1 PE61899 A1 PE 61899A1
Authority
PE
Peru
Prior art keywords
composition
mixtures
conservative
ionic
prostaglandine
Prior art date
Application number
PE1998000177A
Other languages
English (en)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE61899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE61899A1 publication Critical patent/PE61899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION OFTALMICA QUE COMPRENDE a)PROSTAGLANDINA , SUS METABOLITOS, DERIVADOS, SALES Y MEZCLAS; b) CONSERVADOR OFTALMICO, SELECCIONADO ENTRE SULFATO DE POLIMIXINA B, COMPUESTOS DE AMONIO CUATERNARIO; CONSERVADOR DEBIL COMO PEROXIDOS, GENERADORES DE PEROXIDOS Y SUS MEZCLAS; ENTRE OTROS c) UN AGENTE DE AJUSTE DE TONICIDAD NO IONICO PRESENTE EN UNA CONCENTRACION SUFICIENTE PARA i)AJUSTAR LA TONICIDAD DE LA COMPOSICION; ii)INCREMENTAR LA EFECTIVIDAD DEL CONSERVADOR, SELECCIONADO ENTRE MANITOL, SORBITOL, GLICEROL, ENTRE OTROS; d)UN VEHICULO OFTALMICAMENTE ACEPTABLE; COMPRENDE ADEMAS UN AGENTE DE QUELACION COMO EDTA O SU SAL; UN TENSOACTIVO NO IONICO SELECCIONADO DE ESTERES DE ACIDO GRASO DE SORBITAN DE POLIOXIETILENO, ETERES ALQUILICOS DE POLIOEXIETILENO, POLISORBATO 80 Y SUS MEZCLAS, ENTRE OTROS. EL AGENTE ACTIVO ES UN 13,14-DIHIDRO-15-CETO-20-ETIL-PROSTAGLANDINA F2O-ESTER ISOPROPILICO. TAMBIEN COMPRENDE UN REGULADOR DE pH COMO EDTA, BORATOS Y FOSFONATOS, QUE MANTIENE LA COMPOSICION EN UN pH DE 5,5 A 8,5 DURANTE UN ANO. UNA COMPOSICION PREFERIDA ES UN AGENTE ACTIVO DE PROSTAGLANDINA, UN PRIMER TENSOACTIVO NO IONICO COMO POLISORBATO Y UN SEGUNDO TENSOACTIVO NO IONICO COMO COMPUESTO BRIJ Y UN VEHICULO OFTALMICAMENTE ACEPTABLE. LA COMPOSICION PUEDE SER UTIL PARA LA HIPERTENSION OCULAR
PE1998000177A 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico PE61899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
PE61899A1 true PE61899A1 (es) 1999-06-30

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000177A PE61899A1 (es) 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Country Status (33)

Country Link
EP (1) EP0969846B2 (es)
JP (2) JP4920124B2 (es)
KR (1) KR100555818B1 (es)
CN (1) CN1236775C (es)
AR (2) AR002194A1 (es)
AT (1) ATE257385T1 (es)
AU (1) AU738781B2 (es)
BR (2) BRPI9816218B1 (es)
CA (1) CA2280089C (es)
CL (1) CL2009001870A1 (es)
CO (1) CO4940427A1 (es)
CY (1) CY2526B1 (es)
CZ (1) CZ299833B6 (es)
DE (1) DE69820997T3 (es)
DK (1) DK0969846T4 (es)
EE (1) EE04091B1 (es)
ES (1) ES2214706T5 (es)
HK (1) HK1026841A1 (es)
HU (1) HU228896B1 (es)
ID (1) ID22389A (es)
IL (1) IL131041A0 (es)
MY (1) MY122237A (es)
NO (1) NO327713B1 (es)
NZ (1) NZ337322A (es)
PE (1) PE61899A1 (es)
PL (1) PL197509B1 (es)
PT (1) PT969846E (es)
RU (1) RU2197970C2 (es)
SI (1) SI0969846T2 (es)
TW (1) TW527187B (es)
UA (1) UA63938C2 (es)
WO (1) WO1998041208A1 (es)
ZA (1) ZA982188B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
ATE490761T1 (de) * 2000-09-13 2010-12-15 Santen Pharmaceutical Co Ltd Augentropfen
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
DE602005016659D1 (de) * 2004-03-18 2009-10-29 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol-derivat
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN103768070A (zh) * 2006-03-13 2014-05-07 株式会社·R-技术上野 水性组合物
KR20150017002A (ko) * 2006-03-17 2015-02-13 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 눈용 조성물
EP2077829A2 (en) * 2006-10-31 2009-07-15 Alcon Research, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
US20120028910A1 (en) * 2007-10-08 2012-02-02 Jean-Philippe Combal Storage-stable aqueous ophthalmic formulations
WO2009117242A2 (en) * 2008-03-17 2009-09-24 Alcon Research, Ltd. Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PT2787968T (pt) 2011-12-07 2020-06-16 Allergan Inc Administração eficaz de lípidos ao filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
WO2016085885A1 (en) 2014-11-25 2016-06-02 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
CA3113528A1 (en) * 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CN117050817A (zh) 2019-04-12 2023-11-14 埃科莱布美国股份有限公司 抗微生物多用途清洁剂及其制备和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059058T3 (es) * 1990-05-22 1994-11-01 R Tech Ueno Ltd Combinacion sinergica para uso oftalmico.
AU1427592A (en) * 1991-02-07 1992-09-07 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
CA2166722A1 (en) * 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
DE69820997D1 (de) 2004-02-12
PL335168A1 (en) 2000-04-10
DE69820997T3 (de) 2011-10-06
EP0969846B1 (en) 2004-01-07
CZ299833B6 (cs) 2008-12-10
DK0969846T4 (da) 2010-12-20
AR011192A1 (es) 2000-08-02
NO994481L (no) 1999-09-16
CN1249687A (zh) 2000-04-05
HUP0002194A2 (hu) 2000-12-28
CL2009001870A1 (es) 2010-01-22
DE69820997T2 (de) 2004-12-09
NO994481D0 (no) 1999-09-16
HU228896B1 (en) 2013-06-28
AU738781B2 (en) 2001-09-27
EP0969846A1 (en) 2000-01-12
ES2214706T3 (es) 2004-09-16
EE04091B1 (et) 2003-08-15
PL197509B1 (pl) 2008-04-30
IL131041A0 (en) 2001-01-28
CA2280089A1 (en) 1998-09-24
SI0969846T1 (en) 2004-06-30
HUP0002194A3 (en) 2012-08-28
PT969846E (pt) 2004-05-31
NO327713B1 (no) 2009-09-14
WO1998041208A1 (en) 1998-09-24
BR9808016A (pt) 2000-03-08
JP2010043110A (ja) 2010-02-25
UA63938C2 (uk) 2004-02-16
DK0969846T3 (da) 2004-04-13
KR100555818B1 (ko) 2006-03-03
NZ337322A (en) 2001-05-25
KR20000076330A (ko) 2000-12-26
JP4920124B2 (ja) 2012-04-18
CO4940427A1 (es) 2000-07-24
AU7035398A (en) 1998-10-12
BRPI9816218B1 (pt) 2016-04-12
JP2001515502A (ja) 2001-09-18
CY2526B1 (en) 2006-02-08
CA2280089C (en) 2009-03-03
MY122237A (en) 2006-04-29
ID22389A (id) 1999-10-07
TW527187B (en) 2003-04-11
ATE257385T1 (de) 2004-01-15
CN1236775C (zh) 2006-01-18
ES2214706T5 (es) 2011-02-02
RU2197970C2 (ru) 2003-02-10
HK1026841A1 (en) 2000-12-29
SI0969846T2 (sl) 2010-12-31
CZ325799A3 (cs) 2000-01-12
EP0969846B2 (en) 2010-08-25
EE9900410A (et) 2000-04-17
ZA982188B (en) 1998-09-17
AR002194A1 (es) 1998-01-07

Similar Documents

Publication Publication Date Title
PE61899A1 (es) Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico
KR890000098A (ko) 세포 및 조직 수복제
ES2186802T3 (es) Microemulsiones destinadas a usarse como vehiculos para la alimentacion de compuestos activos.
MX172826B (es) Emulsiones acuosas de fluorocarburos estables
CO5011119A1 (es) Jarabe antihistaminico estabilizado
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
DE60104872D1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
DK0572190T3 (da) Oftalmiske præparater indeholdende vitamin E eller en ester deraf som en aktiv ingrediens
KR900002789A (ko) 안과용 용액을 보존하는 방법 및 이를 위한 조성물
RU2002103315A (ru) Офтальмическая композиция, содержащая кетотифен
RU2004129593A (ru) Офтальмическая композиция, содержащая аскомицин
AR247804A1 (es) Composicion biocida sinergica y metodo para proteger con la misma composiciones industriales
ES500581A0 (es) Un procedimiento para la preparacion de una composicion detergente blanqueadora, del tipo que genera peracidos organicos
DE69125360D1 (de) Alkylester von oxidiertem Glutathion
ATE85031T1 (de) Stabilisierung von wasserstoffperoxid.
SE8705064D0 (sv) Emulsion for parenteral administrering
CO5601034A2 (es) Metodos para conservar soluciones oftalmicas y soluciones oftalmicas conservadas
FR2790953B1 (fr) Composition a phase aqueuse continue renfermant de l'acide l-2-oxothiazolidine 4-carboxylique
AR245889A1 (es) Soluciones acuosas autoconservables para la limpieza y conservacion de las lentes de contacto blandas.
FI965157A0 (fi) 2-((2,6-dikloorifenyyli)amiini)fenyyliasetoksietikkahapon uudet suolat orgaanisten emäksisten kationien kanssa
ES2106852T3 (es) Composicion oftalmica que contiene hemihidrato de timolol.
FI842966A0 (fi) Triazolo-pyrimidinderivat, foerfarande foer deras framstaellning samt deras terapeutiska anvaendning som hjaertmediciner.
ES2161200T1 (es) Concentrados liquidos decolorantes-fijadores unitarios.
AR007200A1 (es) Derivados de acido n,n'-di(2-hidroxibencil)etilendiamina-n,n'-diacetico, su aplicacion, su empleo, procedimiento para elaborarlos y preparacionesfarmaceuticas que contienen a dichos derivados.
ES2191859T3 (es) Composiciones enzimaticas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed